CQP: The clinical trial for hydrochloride prasugrel tablets has been approved
CQP announced that its holding subsidiary Chongqing Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for Prasugrel Hydrochloride Tablets. This medication is used to prevent cardiovascular diseases such as acute coronary syndrome and is currently marketed in over 70 countries worldwide, but has not yet been launched in China
According to the Zhitong Finance APP, Chongqing Pharmaceutical Holdings (000950.SZ) announced that its controlling subsidiary, Chongqing Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Chongyao Co., Ltd."), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The clinical trial for Clopidogrel Hydrochloride Tablets will be conducted in the near future.
It is reported that the original manufacturer of Clopidogrel Hydrochloride Tablets is Daiichi Sankyo Company, Limited, which is a third-generation drug that inhibits ADP-induced platelet aggregation. It is indicated for the prevention of acute coronary syndrome, stable angina, and thrombosis in patients with old myocardial infarction after percutaneous coronary intervention. It has been launched in more than 70 countries and regions worldwide (not yet launched in mainland China)
